Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).

Jennifer K. Litton,Douglas Laird,Hope S. Rugo,Johannes Ettl,Sara A. Hurvitz,Miguel Martin,Henri Roché,Young-Hyuck Im,Annabel Goodwin,Joanne L. Blum,Wolfgang Eiermann,Ying Chen,S. Lanzalone,Jijumon Chelliserry,Akos Czibere,Lee A. Albacker,Garrett M. Frampton,Lida A. Mina

Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).

2020

Jennifer K. Litton
Douglas Laird
Hope S. Rugo
Johannes Ettl
Sara A. Hurvitz
Miguel Martin
Henri Roché
Young-Hyuck Im
Annabel Goodwin
Joanne L. Blum
Wolfgang Eiermann
Ying Chen
S. Lanzalone
Jijumon Chelliserry
Akos Czibere
Lee A. Albacker
Garrett M. Frampton
Lida A. Mina

1018Background: Loss-of-function mutations in genes encoding components of the homologous recombination DNA damage response (DDR) machinery, notably BRCA1/2, are associated with tumor sensitivity t...

Keywords:

Gene
Talazoparib
Cancer
advanced breast
Germline
in patient
DNA damage
Pathology
HER2 negative
Cancer research
Medicine
Homologous recombination

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations